305 related articles for article (PubMed ID: 24803836)
41. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients.
Watanabe M; Shibuya A; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Koizumi W
Eur J Intern Med; 2010 Aug; 21(4):333-7. PubMed ID: 20603047
[TBL] [Abstract][Full Text] [Related]
42. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
43. Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure.
Chen T; He Y; Liu X; Yan Z; Wang K; Liu H; Zhang S; Zhao Y
Clin Exp Med; 2012 Sep; 12(3):159-64. PubMed ID: 22002708
[TBL] [Abstract][Full Text] [Related]
44. Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab.
Buensalido JA; Chandrasekar PH
Expert Rev Anti Infect Ther; 2014 Feb; 12(2):151-4. PubMed ID: 24341369
[TBL] [Abstract][Full Text] [Related]
45. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
[TBL] [Abstract][Full Text] [Related]
46. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.
Shibolet O; Ilan Y; Gillis S; Hubert A; Shouval D; Safadi R
Blood; 2002 Jul; 100(2):391-6. PubMed ID: 12091327
[TBL] [Abstract][Full Text] [Related]
47. Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: a clinical survey of 5 cases in Catania, Italy.
Montineri A; Nigro L; La Rosa R; Iacobello C; Larocca L; Cappello E; Fiumara PF; Di Raimondo F; Fatuzzo F
J Clin Virol; 2011 Dec; 52(4):284-7. PubMed ID: 21906994
[TBL] [Abstract][Full Text] [Related]
48. [A case of drug-induced liver injury caused by entecavir for treatment of hepatitis B virus reactivation during RCHOP in a patient with non-Hodgkin lymphoma].
Kondo M; Kitada N; Kobayashi M; Morita S; Yoshioka M; Tsuji T; Mori A; Okamoto T; Watari M
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1199-201. PubMed ID: 19620818
[TBL] [Abstract][Full Text] [Related]
49. Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy.
Ohishi W; Chayama K
Clin Exp Nephrol; 2011 Oct; 15(5):634-640. PubMed ID: 21629993
[TBL] [Abstract][Full Text] [Related]
50. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
[TBL] [Abstract][Full Text] [Related]
51. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma.
Lee IC; Huang YH; Chu CJ; Lee PC; Lin HC; Lee SD
J Chin Med Assoc; 2010 Mar; 73(3):156-60. PubMed ID: 20231001
[TBL] [Abstract][Full Text] [Related]
52. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
Darweesh SK; Gad AA; Akroof K; ElLatif ZA
Eur J Gastroenterol Hepatol; 2019 May; 31(5):607-612. PubMed ID: 30724767
[TBL] [Abstract][Full Text] [Related]
53. [Fulminant hepatic failure with hepatitis B virus reactivation after rituximab treatment in a patient with resolved hepatitis B].
Chung SM; Sohn JH; Kim TY; Yoo KD; Ahn YW; Bae JH; Jeon YC; Choi JH
Korean J Gastroenterol; 2010 Apr; 55(4):266-9. PubMed ID: 20389182
[TBL] [Abstract][Full Text] [Related]
54. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.
Mozessohn L; Chan KK; Feld JJ; Hicks LK
J Viral Hepat; 2015 Oct; 22(10):842-9. PubMed ID: 25765930
[TBL] [Abstract][Full Text] [Related]
55. Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy.
Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H
Intern Med; 2019 Feb; 58(3):375-380. PubMed ID: 30210131
[TBL] [Abstract][Full Text] [Related]
56. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.
Wu Y; Huang H; Luo Y
Front Immunol; 2020; 11():610500. PubMed ID: 33613534
[TBL] [Abstract][Full Text] [Related]
57. Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy.
Kim IK; Kim BG; Kim W; Kim D; Kim YJ; Yoon JH; Lee HS
Antimicrob Agents Chemother; 2012 Nov; 56(11):5511-9. PubMed ID: 22890764
[TBL] [Abstract][Full Text] [Related]
58. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
Fidan S; Capkın E; Arıca DA; Durak S; Okatan IE
Int J Rheum Dis; 2021 Feb; 24(2):254-259. PubMed ID: 33244900
[TBL] [Abstract][Full Text] [Related]
59. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.
Buzo BF; Ramos JF; Marques Rossetti RA; Salles N; Mendrone-Júnior A; Rocha V; de Seixas Santos Nastri AC
Transpl Infect Dis; 2020 Apr; 22(2):e13243. PubMed ID: 31901206
[TBL] [Abstract][Full Text] [Related]
60. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience.
Oh MJ; Lee HJ
Clin Mol Hepatol; 2013 Mar; 19(1):51-9. PubMed ID: 23593610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
